A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

NCT06824467 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

770

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

BIOLOGICAL: Sacituzumab tirumotecan
BIOLOGICAL: Bevacizumab
DRUG: H1 receptor antagonist
DRUG: H2 receptor antagonist
DRUG: Acetaminophen (or equivalent)
DRUG: Dexamethasone (or equivalent)
DRUG: Steroid mouthwash (dexamethasone or equivalent)

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]
[object Object]